HIGHLIGHTS
- who: Chemotherapy Versus Chemotherapy and collaborators from the Department of Oncology, Xiangya Hospital, Central South University, Changsha, China, National Clinical Research Center for have published the article: Cost-Effectiveness Analysis of Sintilimab Combined with Chemotherapy Versus Chemotherapy Alone as the First-Line Treatment for Advanced Esophageal Cancer, in the Journal: (JOURNAL)
- what: The authors assessed patients weighing u2265 60 kg (42%) and and amp;lt; 60 kg (58%), and how this impacted sintilimab use. The main reason for its cost-effectiveness was the low price of camrelizumab ($432 at a dose of 200 mg) due . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.